ArticleMolecular therapy. Oncology2025
Attenuated titin protein expression is associated with advanced stages of ovarian cancer.
Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of chemotherapy on passenger mutations in metastatic colorectal cancer.Molecular oncology · 2026Article
- CCL8 suppresses ovarian cancer progression via M1 macrophage polarization and NF-κB-mediated apoptosis.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study explores the role of titin, a giant muscle protein, in the progression of epithelial ovarian cancer (EOC). We examined titin levels in tissues and sera from EOC patients across stages I-IV and in chemoresistant EOC cells. Tissue samples underwent immunohistochemistry, and serum titin levels were measured using ELISA. Quantitative real-time PCR analyzed titin mRNA in cell lines, including chemosensitive, chemoresistant, and normal ovarian cells. Notably, elevated titin levels were detected in 90.9% of stage I tissues compared to only 14.3% of stage III and IV tissues. Serum titin levels were consistently decreased across all stages relative to healthy controls, with a gradual decrease in expression from stages I to IV. Additionally, titin levels were significantly higher in normal ovarian epithelial cells compared to both chemosensitive and chemoresistant EOC cells, albeit significantly higher in chemosensitive than chemoresistant cells. These findings suggest the possible role of decreased titin levels as a marker for therapeutic intervention, particularly in advanced-stage and chemoresistant EOC. Further elucidation of the mechanisms underlying attenuated titin expression holds promise for advancing our understanding of ovarian cancer pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.